R&D Productivity Still Lags: Study Shows Success Rates May Have Been Overestimated
Executive Summary
Large study tracking drug indications pursued by more than 800 companies over almost a decade finds that only one in 10 wound up getting approved. By therapeutic area, Phase III success rates were lowest in cancer and cardiovascular medicine, and highest in diabetes, infectious and autoimmune disease.